CRDL (Cardiol Therapeutics Inc. Class A Common Shares) Stock Analysis - Financials

Cardiol Therapeutics Inc. Class A Common Shares (CRDL) is a publicly traded Healthcare sector company. As of May 21, 2026, CRDL trades at $1.31 with a market cap of $147.55M and a P/E ratio of 0.00. CRDL moved +3.17% today. Year to date, CRDL is +30.00%; over the trailing twelve months it is +16.07%. Its 52-week range spans $0.77 to $2.24. Analyst consensus is buy with an average price target of $8.50. Rallies surfaces CRDL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are CRDL's key financials?

CRDL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CRDL recently traded at $1.31. Market cap is $147.55M. P/E ratio is 0.00. Revenue is $0.

CRDL Key Metrics

Key financial metrics for CRDL
MetricValue
Price$1.31
Market Cap$147.55M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$2.24
52-Week Low$0.77
Volume0
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

Latest CRDL News

CRDL Analyst Consensus

2 analysts cover CRDL: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.50.

Common questions about CRDL

What are CRDL's key financials?
CRDL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CRDL recently traded at $1.31. Market cap is $147.55M. P/E ratio is 0.00. Revenue is $0.
Is CRDL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CRDL. It does not provide personalized investment advice.
CRDL

CRDL